文献速递免疫规划慢病防控与筛查

英格兰免疫抑制人群Shingrix®疫苗接种率差异:一项基于人群的队列研究

Disparities in uptake of Shingrix® vaccine in immunosuppressed individuals in England: a population-based cohort study.
PubMed 文献 · Vaccine · 2025-12-22

该研究利用英格兰CPRD Aurum初级保健记录(2021年9月1日至2023年8月31日),纳入86,197名70-79岁免疫抑制成人,评估Shingrix®接种率及相关差异。结果显示17.3%至少接种一剂,其中41.5%完成两剂;高龄、少数族裔、贫困及痴呆、严重精神疾病、养老院居住者接种率更低,绝对差异超过5%。

要点

  • 免疫抑制成人中仅17.3%至少接种一剂Shingrix®,完成两剂者占41.5%。
  • 高龄、少数族裔、贫困、痴呆、严重精神疾病及养老院居住者接种率更低。
  • 多种因素相对差异明显但绝对差异多较温和,部分绝对差异超过5%。

核心结论

  • 研究显示英国初始推广阶段免疫抑制成人Shingrix®接种率不理想,高龄、痴呆或严重精神疾病患者及贫困、少数族裔背景人群接种率尤其低。
  • 作者认为需要针对性策略改善该脆弱群体的可及性并减少差异。

研究设计与样本

  • 基于人群的队列研究,使用英格兰参与CPRD Aurum的初级保健记录,时间范围为2021年9月1日至2023年8月31日。
  • 纳入86,197名70-79岁、注册至少一年的免疫抑制成人。

主要发现

  • 17.3%的免疫抑制成人至少接种一剂Shingrix®,其中41.5%完成两剂。
  • 少数族裔接种率较低,例如Black vs. White OR 0.53(95%CI 0.43-0.66)。
  • 最贫困五分位 vs. 最不贫困五分位OR 0.61(95%CI 0.56-0.67)。
  • 绝对差异超过5%的情形包括:痴呆10.3% vs 17.5%,严重精神疾病10.8% vs 17.4%,Black族裔10.0% vs 18.0%,养老院居住5.8% vs 17.5%,贫困最重13.3% vs 最轻21.3%。

关键数值与推荐

  • 主要结局为至少接种一剂Shingrix®;次要结局包括两剂完成、误接Zostavax®(免疫抑制禁忌的减毒活疫苗)及与季节性流感疫苗同时接种。
  • 采用多变量logistic回归估计接种相关因素与接种的关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Herpes zoster (shingles) impacts health and quality of life, particularly in immunosuppressed individuals. The UK Shingrix® zoster vaccination programme has been available for eligible immunosuppressed individuals since 2021. Understanding Shingrix® uptake in immunosuppressed adults is critical for equitable vaccine delivery. METHODS: We conducted a population-based cohort study using primary care records from English practices contributing to Clinical Practice Research Datalink (CPRD) Aurum (1 September 2021-31 August 2023). We included immunosuppressed adults (70-79 years) with at least one year of prior registration. Our primary outcome was uptake of at least one dose of Shingrix®. Secondary outcomes were two-dose completion, inadvertent Zostavax® receipt (live attenuated vaccine contraindicated in immunosuppression), and co-administration of Shingrix® with seasonal influenza vaccine. We used multivariable logistic regression to estimate associations between potential uptake-related factors and vaccine uptake. RESULTS: We included 86,197 immunosuppressed adults, 17.3 % received at least one Shingrix® dose. Of those, 41.5 % received two doses. Uptake was lower in older individuals, people from minority ethnic groups (e.g. Black vs. White OR 0.53, 95 %CI 0.43-0.66), and the most vs. least deprived quintile (OR 0.61, 95 %CI 0.56-0.67). While many factors showed strong relative differences, absolute differences were often modest. Absolute differences exceeded 5 %, highlighting substantial disparity in vaccine coverage, for dementia (10.3 % vs 17.5 %), severe mental illness (10.8 % vs 17.4 %), Black ethnicity (10.0 % vs 18.0 %), care home residence (5.8 % vs 17.5 %), and deprivation (most 13.3 % vs least 21.3 %). CONCLUSIONS: Our study highlights suboptimal Shingrix® vaccine uptake during initial UK roll-out to immunosuppressed adults. Both relative and absolute differences reveal particularly low uptake among older people, those living with dementia or severe mental illness, and individuals from more deprived or minority ethnic backgrounds. Our results suggest a need for targeted strategies to improve access and reduce disparities in this vulnerable group.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Barry EVH, Suffel AM, Walker J, et al. Disparities in uptake of Shingrix® vaccine in immunosuppressed individuals in England: a population-based cohort study. Vaccine. 2025. PMID: 41435736. doi:10.1016/j.vaccine.2025.128078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。